These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 752447)
21. Enhancement of percutaneous absorption by the use of volatile: nonvolatile systems as vehicles. Coldman MF; Poulsen BJ; Higuchi T J Pharm Sci; 1969 Sep; 58(9):1098-102. PubMed ID: 5346073 [No Abstract] [Full Text] [Related]
22. Effect of formulation factors on penetration of hydrocortisone through mouse skin. Shahi V; Zatz JL J Pharm Sci; 1978 Jun; 67(6):789-92. PubMed ID: 660457 [TBL] [Abstract][Full Text] [Related]
23. Gels and other topical corticosteroids. Med Lett Drugs Ther; 1974 Jun; 16(12):50-2. PubMed ID: 4831241 [No Abstract] [Full Text] [Related]
24. The in vivo catabolism of cortisol of by human skin. Greaves MS J Invest Dermatol; 1971 Aug; 57(2):100-7. PubMed ID: 4255498 [No Abstract] [Full Text] [Related]
25. Issues in measuring percutaneous absorption of topical corticosteroids. Maibach HI; Wester RC Int J Dermatol; 1992 Oct; 31 Suppl 1():21-5. PubMed ID: 1428463 [TBL] [Abstract][Full Text] [Related]
26. The effects of topical corticosteroids on human skin. Chan HL Ann Acad Med Singap; 1991 Jan; 20(1):133-8. PubMed ID: 2029153 [TBL] [Abstract][Full Text] [Related]
27. Comparative blanching activities of locally manufactured proprietary fluocinolone acetonide topical preparations. Coleman GL; Magnus AD; Haigh JM; Kanfer I S Afr Med J; 1979 Sep; 56(11):447-9. PubMed ID: 399090 [TBL] [Abstract][Full Text] [Related]
28. Are generic formulations equivalent to trade name topical glucocorticoids? Stoughton RB Arch Dermatol; 1987 Oct; 123(10):1312-4. PubMed ID: 3662563 [TBL] [Abstract][Full Text] [Related]
31. The effect of corticosteroids on human epidermal mitotic activity. Fisher LB; Maibach HI Arch Dermatol; 1971 Jan; 103(1):39-44. PubMed ID: 4321801 [No Abstract] [Full Text] [Related]
32. Results of reflex photometric determinations of vasoconstriction after topical steroid application. Tachyphylaxis, relative and absolute refractory phase after single and multiple application of steroid. Altmeyer P; Cremer C Arch Dermatol Res (1975); 1977 Jan; 257(3):281-5. PubMed ID: 836076 [TBL] [Abstract][Full Text] [Related]
33. Current dangers and problems in the topical use of steroids. Deakin MJ Med J Aust; 1976 Jan; 1(5):120-1. PubMed ID: 772378 [TBL] [Abstract][Full Text] [Related]
34. The case for steroid--antibiotic combinations. Leyden JJ; Kligman AM Br J Dermatol; 1977 Feb; 96(2):179-87. PubMed ID: 843453 [No Abstract] [Full Text] [Related]
35. An autoradiographic study on the percutaneous absorption of a topical corticosteroid, with reference to the effects of occlusive treatment and stripping. Takeda Y J Dermatol; 1975 Sep; 2(3):131-6. PubMed ID: 1107388 [No Abstract] [Full Text] [Related]
36. Percutaneous absorption of 14C-9alpha-fluoro-11beta,21-dihydroxy-3,20-dioxopregna-1,4-dieno (17alpha,16alpha-d)-2'-methyloxazolidine-21-acetate (L 6400) in rats, pigs and humans. Comparison with 3H-triamcinolone acetonide. Lewis JD; Cameron BD; Hawkins DR; Chasseaud LF; Franklin ER Arzneimittelforschung; 1975 Oct; 25(10):1646-50. PubMed ID: 54172 [TBL] [Abstract][Full Text] [Related]
37. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Loftsson T; Stefánsson E Acta Ophthalmol Scand; 2002 Apr; 80(2):144-50. PubMed ID: 11952479 [TBL] [Abstract][Full Text] [Related]
38. Topical steroid therapy in skin disease. A panel discussion. S Afr Med J; 1974 Aug; 48(42):suppl:1-8. PubMed ID: 4278512 [No Abstract] [Full Text] [Related]
39. [On the effect of corticosteroids and other inflammation-inhibiting substances]. Wilbrandt W Schweiz Med Wochenschr; 1966 Sep; 96(35):1136-44. PubMed ID: 5995225 [No Abstract] [Full Text] [Related]
40. Topical corticosteroids. Pace WE Can Med Assoc J; 1973 Jan; 108(1):ll passim. PubMed ID: 4682644 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]